Jiyun Jung

Jiyun Jung

Auto-generated profile, based on publicly available information

Jiyun Jung

Data Management and Statistics Institute, Dongguk University Ilsan Hospital, Goyang, Republic of Korea

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2021 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
JPJae Yoon Park
Jae Yoon Park
JJJiyun Jung
Jiyun Jung
YKYong Chul Kim
Yong Chul Kim
HLHyewon Lee
Hyewon Lee
EKEjin Jin Kim
Ejin Jin Kim
JLJung Pyo Lee
Jung Pyo Lee
As industrialization and urbanization are accelerating, the distribution of green areas is decreasing, particularly in developing countries. Since the 2000s, the effects of surrounding greenness on self-perceived health, including physical and mental health, longevity, and obesity have been reported. However, the effects of surrounding green space on chronic kidney disease are not well understood. Therefore, we investigated the impact of residential greenness on the mortality of chronic kidney disease patients and progression from chronic kidney disease to end-stage renal disease (ESRD). Using a large-scale observational study, we recruited chronic kidney disease patients (n = 64,565; mean age, 54.0 years; 49.0% of male) who visited three Korean medical centers between January 2001 and December 2016. We investigated the hazard ratios of clinical outcomes per 0.1-point increment of exposure to greenness using various models. During the mean follow-up of 6.8 ± 4.6 years, 5,512 chronic kidney disease patients developed ESRD (8.5%) and 8,543 died (13.2%). In addition, a 0.1-point increase in greenness reduced all-cause mortality risk in chronic kidney disease and ESRD patients and progression of chronic kidney disease to ESRD in a fully adjusted model. The association between mortality in ESRD patients and the normalized difference vegetation index was negatively correlated in people aged >65 years, who had normal weight, were nonsmokers, and lived in a nonmetropolitan area. Chronic kidney disease patients who live in areas with higher levels of greenness are at reduced risk of all-cause mortality and progression to ESRD.

31 July 2024 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
YLYoung Hwan Lee
Young Hwan Lee
SLSoyoung Lee
Soyoung Lee
YSYu Jin Seo
Yu Jin Seo
JJJiyun Jung
Jiyun Jung
JLJangwook Lee
Jangwook Lee
JLJeong-Hoon Lim
Jeong-Hoon Lim
Background: This study investigated the association between serum phosphate level and mortality in acute kidney injury (AKI) patients undergoing continuous kidney replacement therapy (CKRT) and evaluated whether this association differed according to disease severity. Methods: Data from eight tertiary hospitals in Korea were retrospectively analyzed. The patients were classified into four groups (low, normal, high, and very high) based on their serum phosphate level at baseline. The association between serum phosphate level and mortality was then analyzed, with further subgroup analysis being conducted according to disease severity. Results: Among the 3,290 patients identified, 166, 955, 1,307, and 862 were in the low, normal, high, and very high phosphate groups, respectively. The 90-day mortality rate was 63.9% and was highest in the very high group (76.3%). Both the high and very high groups showed a significantly higher 90-day mortality rate than did the normal phosphate group (high: hazard ratio [HR], 1.35, 95% confidence interval [CI], 1.21–1.51, p < 0.001; very high: HR, 2.01, 95% CI, 1.78–2.27, p < 0.001). The low group also exhibited a higher 90-day mortality rate than did the normal group among those with high disease severity (HR, 1.47; 95% CI, 1.09–1.99; p = 0.01) but not among those with low disease severity. Conclusion: High serum phosphate level predicted increased mortality in AKI patients undergoing CKRT, and low phosphate level was associated with increased mortality in patients with high disease severity. Therefore, serum phosphate levels should be carefully considered in critically ill patients with AKI.

31 May 2022 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
JLJinwoo Lee
Jinwoo Lee
JJJiyun Jung
Jiyun Jung
JLJangwook Lee
Jangwook Lee
JPJung Tak Park
Jung Tak Park
CJChan-Young Jung
Chan-Young Jung
JPJae Yoon Park
Jae Yoon Park
Background: Comorbid conditions impact the survival of patients with severe acute kidney injury (AKI) who require continuous renal replacement therapy (CRRT). The weights assigned to comorbidities in predicting survival vary based on type of index, disease, and advances in management of comorbidities. We developed a modified Charlson Comorbidity Index (CCI) for use in patients with AKI requiring CRRT (mCCI-CRRT) and improved the accuracy of risk stratification for mortality. Methods: A total of 828 patients who received CRRT between 2008 and 2013, from three university hospital cohorts was included to develop the comorbidity score. The weights of the comorbidities were recalibrated using a Cox proportional hazards model adjusted for demographic and clinical information. The modified index was validated in a university hospital cohort (n = 919) using the data of patients treated from 2009 to 2015. Results: Weights for dementia, peptic ulcer disease, any tumor, and metastatic solid tumor were used to recalibrate the mCCI-CRRT. Use of these calibrated weights achieved a 35.4% (95% confidence interval [CI], 22.1%–48.1%) higher performance than unadjusted CCI in reclassification based on continuous net reclassification improvement in logistic regression adjusted for age and sex. After additionally adjusting for hemoglobin and albumin, consistent results were found in risk reclassification, which improved by 35.9% (95% CI, 23.3%–48.5%). Conclusion: The mCCI-CRRT stratifies risk of mortality in AKI patients who require CRRT more accurately than does the original CCI, suggesting that it could serve as a preferred index for use in clinical practice.

1 March 2026 in Stroke
Verified
Journal Article
Closed access
DGDong-Seok Gwak
Dong-Seok Gwak
WCWoochan Choi
Woochan Choi
Beomjoon KimBeomjoon Kim
Beomjoon Kim
NKNakhoon Kim
Nakhoon Kim
HPHyungjong Park
Hyungjong Park
YKYong-Won Kim
Yong-Won Kim
BACKGROUND: This study aimed to investigate whether net water uptake (NWU) is associated with 3-month catastrophic functional outcome (modified Rankin Scale score, 5–6) and to develop predictive models with preprocedural factors, including NWU, in patients with large infarcts who underwent endovascular thrombectomy. METHODS: This multicenter observational cohort study conducted in Korea included patients with anterior circulation stroke and an Alberta Stroke Program Early Computed Tomography Score (ASPECTS) of ≤5 receiving endovascular thrombectomy between 2015 and 2023. NWU, a quantitative imaging biomarker reflecting the degree of hypoattenuation on noncontrast computed tomography, was measured across the entire ASPECTS region (ASPECTS10-NWU), and its association with catastrophic functional outcome was assessed using a mixed-effects logistic regression model, adjusting for age, sex, prestroke modified Rankin Scale score, baseline National Institutes of Health Stroke Scale score, baseline ASPECTS, onset-to-baseline noncontrast computed tomography time, and intravenous tissue-type plasminogen activator, with hospital included as a random effect. Moreover, a predictive model has been developed with preprocedural factors that were significant covariates from the mixed-effects logistic regression analysis. RESULTS: A total of 255 patients were included (mean age, 71.0±12.6 years; 54.9% male). The median ASPECTS10-NWU was 3.0% (interquartile range, 1.9%–4.1%). Higher ASPECTS10-NWU was independently associated with catastrophic functional outcome (adjusted odds ratio, 1.70 [95% CI, 1.33–2.17]; P <0.001). The model integrating ASPECTS10-NWU with preprocedural variables suggested predicted catastrophic functional outcome probabilities; as ASPECTS10-NWU and baseline National Institutes of Health Stroke Scale score increased, the marginal probability of catastrophic functional outcome increased in all age (<80 and ≥80 years) and prestroke modified Rankin Scale score (0–1 and 2–4) groups, with the patients aged ≥80 years and with prestroke modified Rankin Scale score of 2 to 4 having higher outcome probability. CONCLUSIONS: Elevated ASPECTS10-NWU is strongly associated with catastrophic functional outcome in patients with large infarcts treated with endovascular thrombectomy. Integrating the ASPECTS10-NWU with clinical variables may provide patient-specific prognostication that may assist clinicians in decision-making for endovascular thrombectomy in large infarcts.

31 July 2024 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
CJChan-Young Jung
Chan-Young Jung
JJJiyun Jung
Jiyun Jung
JLJeong-Hoon Lim
Jeong-Hoon Lim
JPJin Hyuk Paek
Jin Hyuk Paek
KKKipyo Kim
Kipyo Kim
CBChung Hee Baek
Chung Hee Baek
Background: Identifying risk factors and improving prognostication for mortality among patients with sepsis-associated acute kidney injury (AKI) undergoing continuous kidney replacement therapy (CKRT) is important in improving the adverse prognosis of this patient population. This study aimed to compare the prognostic value of existing systemic inflammation biomarkers and determine the optimal systemic inflammation biomarker in patients with sepsis-associated AKI receiving CKRT. Methods: This multi-center, retrospective, observational cohort study included 1,500 patients with sepsis-associated AKI treated with intensive care and CKRT. The main predictor was a panel of 13 different systemic inflammation biomarkers. The primary outcome was 28-day mortality after CKRT initiation. Secondary outcomes included 90-day mortality after CKRT initiation, CKRT duration, kidney replacement therapy dependence at discharge, and lengths of intensive care unit (ICU) and hospital stays. Results: When added to the widely accepted Acute Physiology and Chronic Health Evaluation II score, platelet-to-albumin ratio (PAR) and neutrophil-platelet score (NPS) had the highest improvements in prognostication of 28-day mortality, where the corresponding increases in C-statistic were 0.01 (95% confidence interval [CI], 0.00–0.02) and 0.02 (95% CI, 0.01–0.03). Similar findings were observed for 90-day mortality. The 28- and 90-day mortality rates were significantly lower for the higher PAR and NPS quartiles. These associations remained significant even after adjustment for potential confounding variables in multivariable Cox proportional hazards models. Conclusion: Of the available systemic inflammation biomarkers, the addition of PAR or NPS to conventional ICU prediction models improved the prognostication of patients with sepsis-associated AKI receiving intensive care and CKRT.

12 January 2024 in Kidney Research and Clinical Practice
Verified
Journal Article
Open access
PDF file
DLDongyeon Lee
Dongyeon Lee
JJJiyun Jung
Jiyun Jung
SKSichan Kim
Sichan Kim
JLJaeyun Lee
Jaeyun Lee
JLJangwook Lee
Jangwook Lee
HKHyosang Kim
Hyosang Kim
Posttransplantation diabetes mellitus (PTDM) is a crucial problem after kidney transplantation. We aimed to determine whether metformin affects cardiovascular and graft outcomes in patients with PTDM. This retrospective cohort study included 1,663 kidney transplant recipients without preexisting diabetes mellitus. The patients were divided into metformin and non-metformin groups, with matched propensity scores. We also estimated metformin's effect on percutaneous coronary intervention (PCI), major adverse cardiovascular events (MACEs), acute rejection, and graft failure. Of 634 recipients with PTDM, 406 recipients were treated with metformin. The incidence of PCI was 2.4% and 7.1% in the metformin and non-metformin groups, respectively (p = 0.04). The metformin group exhibited a lower risk of PCI in Cox regression analyses (hazard ratio [HR], 0.27; 95% confidence interval [CI], 0.10-0.77; p = 0.014), especially in subgroups with male sex, age over 49 years (median), long-term metformin use (mean of ≥1,729 days), and simultaneous tacrolimus administration. Long-term metformin use was also associated with lower incidence of MACEs (HR, 0.09; 95% CI, 0.01-0.67; p = 0.02). Incidence of graft failure was 9.9% and 17.0% in the metformin and non-metformin groups, respectively (p = 0.046). Both long-term use and higher dose of metformin, as well as tacrolimus administration with metformin, were associated with a lower risk of graft failure (HR, 0.29; 95% CI, 0.11-0.75; p = 0.01; HR, 0.39; 95% CI, 0.18-0.85; p = 0.02; and HR, 0.39; 95% CI, 0.19-0.79; p = 0.009, respectively). Metformin use is associated with a decreased risk of developing coronary artery disease and better graft outcomes in PTDM.